bjh

british journal of haematology

Volume 129, 2005 Pages 1–862

Issue 1, April-I 2005

Images in Haematology

1 ***Scleromalacia perforans*** **complicating graft-*versus*-host disease**
C. Hon, R. W. K. Law and W. Y. Au

2 **Sinus zygomycosis in a patient receiving voriconazole prophylaxis**
M. S. Lionakis and D. P. Kontoyiannis

Reviews

3 **The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care**
C. Casper

18 **Biology and management of relapsed acute myeloid leukaemia**
C. Craddock, S. Tauro, P. Moss and D. Grimwade

Haematological Malignancy

35 **Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukaemia: results of the Medical Research Council ALL 97 trial**
A. Roy, M. Bradburn, A. V. Moorman, J. Burrett, S. Love, S. E. Kinsey, C. Mitchell, A. Vora, T. Eden, J. S. Lilleyman, I. Hann and V. Saha on behalf of the Medical Research Council Childhood Leukaemia Working Party

45 **Interphase FISH to detect *PBX1/E2A* fusion resulting from the der(19)t(1;19)(q23;p13.3) or t(1;19)(q23;p13.3) in paediatric patients with acute lymphoblastic leukaemia**
B. M. Shearer, H. C. Flynn, R. A. Knudson and R. P. Ketterling

53 **p53 Aberrations do not predict individual response to fludarabine in patients with B-cell chronic lymphocytic leukaemia in advanced stages Rai III/IV**
M. Valgañón, P. Giraldo, X. Agirre, M. J. Larráyoz, A. Rubio-Martinez, D. Rubio-Felix, M. J. Calasanz and M. D. Odero

60 **Aberrant methylation of the negative regulators *RASSFIA*, *SHP-1* and *SOCS-1* in myelodysplastic syndromes and acute myeloid leukaemia**
M. F. Johan, D. T. Bowen, M. E. Frew, A. C. Goodeve and J. T. Reilly

66 **Gains on 9p are common genomic aberrations in idiopathic myelofibrosis: a comparative genomic hybridization study**
O. Al-Assar, A. Ul-Hassan, R. Brown, G. A. Wilson, D. W. Hammond and J. T. Reilly

Platelets, Haemostasis and Thrombosis

72 **Risks factors for highly unstable response to oral anticoagulation: a case-control study**
G. Palareti, C. Legnani, G. Guazzaloca, V. Lelia, B. Cosmi, B. Lunghi, G. Marchetti, D. Poli and V. Pengo on behalf of the ad hoc study group of the Italian Federation of Anticoagulation Clinics

79 **Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? No answer yet**
G. Rock, D. Anderson, W. Clark, P. Leblond, D. Palmer, M. Sternbach, D. Sutton and G. Wells members of the Canadian Apheresis Group and members of the Canadian Association of Apheresis Nurses

87 **A single-centre prospective study of clinical and haemostatic risk factors for venous thromboembolism following lower limb arthroplasty**
J. E. Joseph, J. Low, B. Courtenay, M. J. Neil, M. McGrath and D. Ma

93 **FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay**
K. Kokame, Y. Nobe, Y. Kokubo, A. Okayama and T. Miyata

101 **A serine-rich glycoprotein of *Streptococcus sanguis* mediates adhesion to platelets via GPIb**
C. Plummer, H. Wu, S. W. Kerrigan, G. Meade, D. Cox and C. W. I. Douglas

Haemopoiesis and Leucocytes

110 **A third course of anti-thymocyte globulin in aplastic anaemia is only beneficial in previous responders**
V. Gupta, E. C. Gordon-Smith, G. Cook, A. Parker, J. K. M. Duguid, K. M. O. Wilson, Q.-L. Yi and J. C. W. Marsh

118 **Immunomodulatory effect of human adipose tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells**
B. Puissant, C. Barreau, P. Bourin, C. Clavel, J. Corre, C. Bousquet, C. Taureau, B. Cousin, M. Abbal, P. Laharrague, L. Penicaud, L. Casteilla and A. Blancher

Red Cells and Iron

130 **Expression of phosphatidylserine (PS) on wild-type and Gerbich variant erythrocytes following glycophorin-C (GPC) ligation**
D. J. Head, Z. E. Lee, J. Poole and N. D. Avent

138 **Gene expression profiling in polycythaemia vera: overexpression of transcription factor NF-E2**
P. S. Goerttler, C. Kreutz, J. Donauer, D. Faller, T. Maiwald, E. März, B. Rumberger, T. Sparna, A. Schmitt-Gräff, J. Wilpert, J. Timmer, G. Walz and H. L. Pahl

Transfusion

151 **Alloimmunization to red blood cell antigens after universal leucodepletion. A regional multicentre retrospective study**
H. Schonewille and A. Brand

Correspondence

157 **Iron mobilisation from transferrin by deferiprone (L1)**
G. J. Kontoghiorghes, A. Kolnagou, E. Eracleous and R. W. Evans

157 **Criteria for defining a complete remission in acute myeloid leukaemia**
H. Yarranton

158 **Response to Yarranton**
G. de Greef, W. van Putten and B. Lowenberg

158 **Amyloidosis, not myeloma**
H. J. B. Goodman, A. D. Wechalekar and P. N. Hawkins

159 **Response to Goodman *et al.*: Amyloidosis, not myeloma**
J. Anthony Child, G. Morgan and G. Jackson

160 **Thyrotoxic periodic paralysis after allogeneic haematopoietic stem cell transplantation**
W. Y. Au, A. K. Lie, A. W. Kung, W. Mak and Y. L. Kwong

162 **Erratum**

Issue 2, April-II 2005

Images in Haematology

163 **Bone relapse in a patient with acute lymphoblastic leukaemia**
I. Aydogdu, A. M. Erkurt, E. Kaya and I. Kuku

164 **Dutcher–Fahey intranuclear inclusions in multiple myeloma**
E. S. K. Ma and T. W. H. Shek

Reviews

165 **Primary and secondary thrombocytosis in childhood**
C. Dame and A. H. Sutor

178 **Gaucher disease: pathological mechanisms and modern management**
M. Jmoudiak and A. H. Futerman

Haematological Malignancy

189 **Cellular drug sensitivity in *MLL*-rearranged childhood acute leukaemia is correlated to partner genes and cell lineage**
J. Palle, B. M. Frost, E. Forestier, G. Gustafsson, P. Nygren, M. Hellebostad, O. G. Jonsson, J. Kanerva, K. Schmiegelow, R. Larsson and G. Lönnerholm on behalf of the Nordic Society for Paediatric Haemotology and Oncology

199 **Hodgkin's disease variant of Richter's syndrome in chronic lymphocytic leukaemia patients previously treated with fludarabine**
D. Fong, A. Kaiser, G. Spizzo, G. Gastl and A. Tzankov

206 **Impact of epoetin-β on survival of patients with lymphoproliferative malignancies: long-term follow up of a large randomized study**
A. Österborg, Y. Brandberg and M. Hedenus

210 **Del (9q) AML: clinical and cytological characteristics and prognostic implications**
A. Peniket, J. Wainscoat, L. Side, S. Daly, R. Kusec, G. Buck, K. Wheatley, H. Walker, S. Chatters, C. Harrison, J. Boultwood, A. Goldstone and A. Burnett

Transplantation

221 **A UGT2B17-positive donor is a risk factor for higher transplant-related mortality and lower survival after bone marrow transplantation**
S. Terakura, M. Murata, T. Nishida, N. Emi, Y. Akatsuka, S. R. Riddell, Y. Morishima, Y. Kodera and T. Naoe

229 **Increased incidence of EBV-related disease following paediatric stem cell transplantation with reduced-intensity conditioning**
J. Cohen, M. Gandhi, P. Naik, D. Cubitt, K. Rao, U. Thaker, E. G. Davies, H. B. Gaspar, P. J. Amrolia and P. Veys

Platelets, Haemostasis and Thrombosis

240 **Anti-prothrombin IgG from patients with anti-phospholipid antibodies inhibits the inactivation of factor Va by activated protein C**
M. Galli, G. M. Willems, J. Rosing, R. M. Janssen, J. W. P. Govers-Riemslag, P. Comfurius, T. Barbui, R. F. A. Zwaal and E. M. Bevers

Haemopoiesis and Leucocytes

248 **Bone marrow endothelial cells in multiple myeloma secrete CXC-chemokines that mediate interactions with plasma cells**
A. Pellegrino, R. Ria, G. Di Pietro, T. Cirulli, G. Surico, A. Pennisi, F. Morabito, D. Ribatti and A. Vacca

257 **Nicotinic acetylcholine receptor-mediated stimulation of endothelial cells results in the arrest of haematopoietic progenitor cells on endothelium**
N. Serobyan, I. U. Schraufstatter, A. Strongin and S. K. Khaldoyanidi

266 **The immune response to primary EBV infection: a role for natural killer cells**
H. Williams, K. McAulay, K. F. Macsween, N. J. Gallacher, C. D. Higgins, N. Harrison, A. J. Swerdlow and D. H. Crawford

Short reports

275 **Heterogeneous expression pattern of pro- and anti-apoptotic factors in myeloid progenitor cells of patients with severe congenital neutropenia treated with granulocyte colony-stimulating factor**
G. Cario, J. Skokowa, Z. Wang, V. Bucan, C. Zeidler, M. Stanulla, M. Schrappe and K. Welte

279 **Teicoplanin-dependent antibodies: detection and characterization**
S. F. Garner, K. Campbell, G. Smith, C. Hurd, S. J. Davidson, M. Treacy, J. F. Burman, H. Kroll and W. H. Ouwehand

Red Cells and Iron

282 **Co-inheritance of the Hb Sun Prairie mutation with a point mutation at 5′-UTR in the eastern Indian population**
A. A. Sarkar, C. Mukhopadhyay, S. Chandra, S. Banerjee, M. K. Das and U. B. Dasgupta

287 **Corrigendum**

Announcements

288 **The Baxter/Royal College of Pathologists Training Fellowship Haematology**

289 **Information sheet**

Issue 3, May-I 2005

Images in Haematology

291 **Drug-induced haemolysis and methaemoglobinaemia in glucose 6-phosphate dehydrogenase deficiency**
B. I. Dalal and C. Kollmannsberger

292 **Transfusion-related acute lung injury**
J. P. Quinn and P. T. Murphy

Reviews

293 **Pregnancy and its management in the Philadelphia negative myeloproliferative diseases**
C. Harrison

307 **Molecular mechanisms of fibrinolysis**
G. Cesarman-Maus and K. A. Hajjar

Haematological Malignancy

322 **Killing of non-Hodgkin lymphoma cells by autologous CD19 engineered T cells**
E. J. Cheadle, D. E. Gilham, F. C. Thistlethwaite, J. A. Radford and R. E. Hawkins

333 **Somatic *PTPN11* mutations in childhood acute myeloid leukaemia**
M. Tartaglia, S. Martinelli, I. Iavarone, G. Cazzaniga, M. Spinelli, E. Giarin, V. Petrangeli, C. Carta, R. Masetti, M. Aricò, F. Locatelli, G. Basso, M. Sorcini, A. Pession and A. Biondi

340 **Fusion hybrids of dendritic cells and autologous myeloid blasts as a potential cellular vaccine for acute myeloid leukaemia**
M. Klammer, M. Waterfall, K. Samuel, M. L. Turner and P. H. Roddie

350 **Prognosis of patients with acute myeloid leukaemia admitted to intensive care**
A. Rabbat, D. Chaoui, D. Montani, O. Legrand, A. Lefebvre, B. Rio, N. Roche, C. Lorut, J.-P. Marie and G. Huchon

358 **Haplotypes in the tumour necrosis factor region and myeloma**
G. J. Morgan, P. J. Adamson, F. K. Mensah, C. F. Spink, G. R. Law, L. J. Keen, E. Roman, F. E. Davies, S. Rollinson, J. A. Child and J. L. Bidwell

366 **The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas**
R. Sonnen, W.-P. Schmidt, H. K. Müller-Hermelink and N. Schmitz

Short reports

373 **Aberrant somatic hypermutation and expression of activation-induced cytidine deaminase mRNA in mediastinal large B-cell lymphoma**
C. Bödör, Á. Bognár, L. Reiniger, Á. Szepesi, E. Tóth, L. Kopper and A. Matolcsy

377 **Targeting primary human leukaemia cells with RNA interference: Bcr-Abl targeting inhibits myeloid progenitor self-renewal in chronic myeloid leukaemia cells**
J. M. E. Withey, S. B. Marley, J. Kaeda, A. J. Harvey, M. R. Crompton and M. Y. Gordon

Transplantation

381 **Prognostic relevance of 'early-onset' graft-*versus*-host disease following non-myeloablative haematopoietic cell transplantation**
M. Mielcarek, L. Burroughs, W. Leisenring, R. Diaconescu, P. J. Martin, B. M. Sandmaier, D. G. Maloney, M. B. Maris, T. R. Chauncey, J. A. Shizuru, K. G. Blume, U. Hegenbart, D. Niederwieser, S. Forman, B. Bruno, A. Woolfrey and R. Storb

392 **UTY-specific TCR-transfer generates potential graft-*versus*-leukaemia effector T cells**
R. Ivanov, S. Hol, T. Aarts, A. Hagenbeek, E. H. Slager and S. Ebeling

403 **One *versus* two high-dose cytarabine-based consolidation before autologous stem cell transplantation for young acute myeloblastic leukaemia patients in first complete remission**
E. Jourdan, F. Rigal-Huguet, G. Marit, N. Vey, N. Dastugue, N. Fegueux, L. Molina, J.-A. Gastaut, L. Legros, H. Zerazhi, S. Cailleres, F. Bauduer, D. Bordessoule, M. Attal, D. Blaise and A. Pigneux for the BGMT Study Group

411 **Efficient identification of T-cell clones associated with graft-*versus*-host disease in target tissue allows for subsequent detection in peripheral blood**
R. C. Beck, M. Wlodarski, L. Gondek, K. S. Theil, R. J. Tuthill, R. Sobeck, B. Bolwell and J. P. Maciejewski

Haemopoiesis and Leucocytes

420 **Resolving and classifying haematopoietic bone-marrow cell populations by multi-dimensional analysis of flow-cytometry data**
E. Zamir, B. Geiger, N. Cohen, Z. Kam and B.-Z. Katz

Short report

432 **Identification of *DKC1* gene mutations in Japanese patients with X-linked dyskeratosis congenita**
H. Kanegane, Y. Kasahara, J. Okamura, T. Hongo, R. Tanaka, K. Nomura, S. Kojima and T. Miyawaki

Red Cells and Iron

435 **Chronic oxidative stress reduces the respiratory burst response of neutrophils from beta-thalassaemia patients**
J. Amer and E. Fibach

Correspondence

442 **Coombs' negative haemolytic anaemia as a first manifestation of autoimmune lymphoproliferative disease**
C. Guitton, F. Le Deist and B. Bader-Meunier

443 **Microchimerism detection by human leucocyte antigen-specific quantitative-polymerase chain reaction analysis in recipients of allogeneic Epstein–Barr virus-specific cytotoxic T lymphocytes**
K. G. Lucas, J. L. Nelson, T. D. Erickson and Q. Sun

444 **All-trans retinoic acid induced cardiac and skeletal myositis in induction therapy of acute promyelocytic leukaemia**
F. Fabbiano, S. Magrin, C. Cangialosi, R. Felice, S. Mirto and F. Pitrolo

446 **'Leukaemic' presentation of metastatic Merkel cell carcinoma**
C. S. Tam, P. Turner, C. McLean, S. Whitehead and M. Cole-Sinclair

Issue 4, May-II 2005

Images in Haematology

447 **Severe conidiobolomycosis complicating induction chemotherapy in a patient with acute lymphoblastic leukaemia**
D. C. L. Tan, L. Y. Hsu, L. P. Koh, Y. T. Goh and M. Koh

448 **Loss of skin pigment caused by imatinib therapy**
S. McPartlin and M. Leach

Reviews

449 **Chronic sickle cell lung disease: new insights into the diagnosis, pathogenesis and treatment of pulmonary hypertension**
R. F. Machado and M. T. Gladwin

465 **Predicting clinical severity in sickle cell anaemia**
M. H. Steinberg

482 **Bone involvement in sickle cell disease**
A. Almeida and I. Roberts

Haematological Malignancy

491 **Co-existence of multiple subclones in TEL-AML1 at diagnosis of acute lymphoblastic leukaemia in association with submicroscopic deletion of AML1**
R. Rothman, L. Trakhtenbrot, B. Bielorai, S. Izraeli, G. Ishoev, N. Amariglio, G. Rechavi and A. Toren

499 **Immunoglobulin gene segment usage, location and immunogenicity in mutated and unmutated chronic lymphocytic leukaemia**
K. Mauerer, D. Zahrieh, G. Gorgun, A. Li, J. Zhou, S. Ansén, L. Z. Rassenti and J. G. Gribben

511 **Phenotype and frequency of Epstein–Barr virus-infected cells in pretreatment blood samples from patients with Hodgkin lymphoma**
G. Khan, A. Lake, L. Shield, J. Freeland, L. Andrew, F. E. Alexander, R. Jackson, P. R. A. Taylor, E. A. B. McCruden and R. F. Jarrett

520 **Interphase molecular cytogenetic screening for chromosomal abnormalities of prognostic significance in childhood acute lymphoblastic leukaemia: a UK Cancer Cytogenetics Group Study**
C. J. Harrison, A. V. Moorman, K. E. Barber, Z. J. Broadfield, K. L. Cheung, R. L. Harris, G. R. Jalali, H. M. Robinson, J. C. Strefford, A. Stewart, S. Wright, M. Griffiths, F. M. Ross, L. Harewood and M. Martineau

Short reports

531 **Expression of the Rho-family GTPase gene *RHOF* in lymphocyte subsets and malignant lymphomas**
L. G. Gouw, N. S. Reading, S. D. Jenson, M. S. Lim and K. S. J. Elenitoba-Johnson

534 **Use of mycophenolate mofetil for chronic, refractory immune cytopenias in children with autoimmune lymphoproliferative syndrome**
V. K. Rao, F. Dugan, J. K. Dale, J. Davis, J. Tretler, J. K. Hurley, T. Fleisher, J. Puck and S. E. Straus

539 **The absence of CD56 on malignant plasma cells in the cerebrospinal fluid is the hallmark of multiple myeloma involving central nervous system**
H. Chang, E. S. Bartlett, B. Patterson, C. I. Chen and Q. L. Yi

Transplantation

542 **Chimaerism analyses and subsequent immunological intervention after stem cell transplantation in patients with juvenile myelomonocytic leukaemia**
A. Yoshimi, C. M. Niemeyer, V. Bohmer, U. Duffner, B. Strahm, H. Kreyenberg, D. Dilloo, F. Zintl, A. Claviez, W. Wössmann, B. Kremens, W. Holter, D. Niethammer, J. F. Beck, U. Kontny, P. Nöllke, T. Klingebiel and P. Bader

Short report

550 **Brain parenchymal damage after haematopoietic stem cell transplantation for severe sickle cell disease**
P. Woodard, K. J. Helton, R. B. Khan, G. A. Hale, S. Phipps, W. Wang, R. Handgretinger and J. M. Cunningham

Platelets, Haemostasis and Thrombosis

553 **Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis**
Y. Chait, B. Condat, D. Cazals-Hatem, P. Rufat, S. Atmani, D. Chaoui, F. Guilmin, J. J. Kiladjian, A. Plessier, M. H. Denninger, N. Casadevall, D. Valla and J. B. Brière

Correspondence

561 **Protein Z-dependent protease inhibitor W303X mutation in venous thrombosis**
R. González-Conejero, E. Pérez-Ceballos, V. Vicente and J. Corral

562 **Protein Z-dependent protease inhibitor W303X mutation in venous thrombosis: response to Gonzalez-Conejero *et al***
P. Harper

562 **Bone marrow biopsy in thrombocytopenic or anticoagulated patients**
J. W. Eikelboom

564 **The role of natural killer T (NKT) cells in immune thrombocytopenia: is strong *in vitro* NKT cell activity related to the development of remission?**
U. Johansson, M. G. Macey, D. Kenny, A. B. Provan and A. C. Newland

Announcement

566 **UK NEQAS for Blood Coagulation Annual Scientific Meeting and Special Symposium in Honour of Professor Eric Preston Sheffield Hallam University, Sheffield, UK 8–9 June 2005**

Issue 5, June-I 2005

Images in Haematology

567 **Childhood essential thrombocythaemia**
N. B. A. Roy, M. Treacy and P. Kench

568 **Hypereosinophilia in acute B-lineage lymphoblastic leukaemia**
F. Girodon, E. Bergoin, B. Favre, S.-A. Martha, F. Mugneret, G. Couillault, P.-M. Carli and M. Maynadié

Reviews

569 **The immune response to fungal infections**
S. Shoham and S. M. Levitz

583 **Cytokines and fungal infections**
C. Antachopoulos and E. Roilides

Haematological Malignancy

597 **A population-based study of severity of comorbidity among patients with non-Hodgkin's lymphoma: prognostic impact independent of International Prognostic Index**
M. L. G. Janssen-Heijnen, D. J. van Spronsen, V. E. P. P. Lemmens, S. Houterman, K. D. G. W. Verheij and J. W. W. Coebergh

607 **Long-term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high-dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments**
C. L. Alvares, F. E. Davies, C. Horton, G. Patel, R. Powles, B. Sirohi, R. Zuha, A. Gatt, R. Saso, J. G. Treleaven, C. E. Dearden, M. N. Potter, M. E. Ethell and G. J. Morgan

Short reports

615 **Epstein-Barr virus-associated familial Hodgkin lymphoma: paediatric onset in three of five siblings**
P. M. Kamper, E. Kjeldsen, N. Clausen, K. Bendix, S. Hamilton-Dutoit and F. d'Amore

618 **Polymorphisms in cytochrome P450 17A1 and risk of non-Hodgkin lymphoma**
C. F. Skibola, T. Lightfoot, L. Agana, A. Smith, S. Rollinson, A. Kao, P. Adamson, G. J. Morgan, M. T. Smith and E. Roman

Transplantation

622 **Haematopoietic stem cell transplantation in haemophagocytic lymphohistiocytosis**
A. Horne, G. Janka, R. M. Egeler, H. Gadner, S. Imashuku, S. Ladisch, F. Locatelli, S. M. Montgomery, D. Webb, J. Winiarski, A. H. Filipovich and J.-I. Henter for the Histiocyte Society

631 **Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma**
N. Kröger, B. Shaw, S. Iacobelli, T. Zabelina, K. Peggs, A. Shimoni, A. Nagler, T. Binder, T. Eiermann, A. Madrigal, R. Schwerdtfeger, M. Kiehl, H. G. Sayer, J. Beyer, M. Bornhäuser, F. Ayuk, A. R. Zander and D. I. Marks for the Clinical Trial Committee of the British Society of Blood and Marrow Transplantation and the German Cooperative Transplant Group

Platelets, Haemostasis and Thrombosis

644 **The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine**
M. Böhm, C. Betz, W. Miesbach, M. Krause, C. von Auer, H. Geiger and I. Scharrer

653 **Reduced efficacy of clinical probability score and D-dimer assay in elderly subjects suspected of having deep vein thrombosis**
R. E. G. Schutgens, F. J. L. M. Haas and D. H. Biesma

Haemopoiesis and Leucocytes

658 **Subtyping of natural killer cell cytotoxicity deficiencies in haemophagocytic lymphohistocytosis provides therapeutic guidance**
A. Horne, C. Zheng, I. Lorenz, M. Löfstedt, S. M. Montgomery, G. Janka, J.-I. Henter and E. M. Schneider

667 **Evidence for a link between sphingolipid metabolism and expression of CD1d and MHC-class II: monocytes from Gaucher disease patients as a model**
A. Balreira, L. Lacerda, C. Sá Miranda and F. A. Arosa

677 **Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway**
R. Bortul, P. L. Tazzari, A. M. Billi, G. Tabellini, I. Mantovani, A. Cappellini, T. Grafone, G. Martinelli, R. Conte and A. M. Martelli

687 **Fusion of dendritic cells with multiple myeloma cells results in maturation and enhanced antigen presentation**
B. Vasir, V. Borges, Z. Wu, D. Grosman, J. Rosenblatt, M. Irie, K. Anderson, D. Kufe and D. Avigan

Red Cells and Iron

701 **An elevated venous haemoglobin concentration cannot be used as a surrogate marker for absolute erythrocytosis: a study of patients with polycythaemia vera and apparent polycythaemia**
P. L. Johansson, S. Safai-Kutti and J. Kutti

Correspondence

706 **Evaluation and prognostic value of serum osteoprotegerin in multiple myeloma**
S. Depil, C. Mathiot, X. Leleu, A. S. Moreau, J.-L. Faucompré, B. Hennache, F. Bauters, R. Bataille and T. Facon

707 **Imported malaria is a major cause of thrombocytopenia in children presenting to the emergency department in east London**
S. Ladhani, P. Khatri, H. El-Bashir and D. Shingadia

709 **High incidence of haemostatic interference in cancer patients treated with FOLFOX regimen and concomitant minidose of warfarin**
M. Magagnoli, G. Masci, L. Castagna, S. Bramanti, E. Morenghi, C. Carnaghi and A. Santoro

Issue 6, June-II 2005

Images in Haematology

711 **Cerebral and pulmonary nocardia in a bone marrow transplant patient**
A. D. Laurence and K. S. Peggs

712 **Heparin-induced skin necrosis**
R. Patel, Z. Lim, S. Dawe, J. Salisbury and R. Arya

Reviews

713 **Susceptibility to infection in patients with neutropenia: the role of the innate immune system**
O. W. Neth, M. Bajaj-Elliott, M. W. Turner and N. J. Klein

723 **Psychological complications in sickle cell disease**
K. A. Anie

Annotation

730 **Courting the expert: a clash of culture?**
P. Caldwell

Haematological Malignancy

734 **Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial**
C. D. Mitchell, S. M. Richards, S. E. Kinsey, J. Lilleyman, A. Vora and T. O. B. Eden on behalf of the Medical Research Council Childhood Leukaemia Working Party

746 **LISA: a web-based decision-support system for trial management of childhood acute lymphoblastic leukaemia**
J. Bury, C. Hurt, A. Roy, L. Cheesman, M. Bradburn, S. Cross, J. Fox and V. Saha

755 **PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma**
H. E. Oakervee, R. Popat, N. Curry, P. Smith, C. Morris, M. Drake, S. Agrawal, J. Stec, D. Schenkein, D.-L. Esseltine and J. D. Cavenagh

763 **Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma**
C. Kyriakou, K. Thomson, S. D'Sa, A. Flory, J. Hanslip, A. H. Goldstone and K. L. Yong

771 **Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients**
F. Cervantes, A. Alvarez-Larrán, A. Domingo, E. Arellano-Rodrigo and E. Montserrat

776 **Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma**
S. Jagannath, B. G. M. Durie, J. Wolf, E. Camacho, D. Irwin, J. Lutzky, M. McKinley, E. Gabayan, A. Mazumder, D. Schenkein and J. Crowley

784 **Genetic analysis of the 2q33 region containing *CD28–CTLA4–ICOS* genes: association with non-Hodgkin's lymphoma**
G. Piras, M. Monne, A. Uras, A. Palmas, M. Murineddu, L. Arru, A. Bianchi, A. Calvisi, L. Curreli, E. Gaviano, P. Lai, A. Murgia, G. C. Latte, A. Noli and A. Gabbas

Short report 791 **SHP1 expression in bone marrow biopsies of myelodysplastic syndrome patients: a new prognostic factor**
A. V. Mena-Duran, S. H. Togo, L. Bazhenova, J. Cervera, K. Bethel, M. L. Senent, J. Nieva, G. F. Sanz, M. A. Sanz, A. Saven and T. Mustelin

Transplantation

795 **Outcomes of patients with acute leukaemia who relapsed after reduced-intensity stem cell transplantation from HLA-identical or one antigen-mismatched related donors**
K. Kobayashi, M. Kami, N. Murashige, E. Kusumi, Y. Kishi, T. Hamaki, A. Hori, T. Matsumura, K. Yuji, S. Masuo, S. Mori, S. Miyakoshi, R. Tanosaki, T. Mitamura, Y. Takaue and S. Taniguchi for the Tokyo SCT Consortium Institution

Platelets, Haemostasis and Thrombosis

803 **Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease**
U. H. Athale, S. A. Siciliano, M. Crowther, R. D. Barr and A. K. C. Chan

811 **Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study**
A. Cortelezzi, M. Moia, A. Falanga, E. M. Pogliani, G. Agnelli, E. Bonizzoni, G. Gussoni, T. Barbui and P. Mannuccio Mannucci on behalf of the CATHEM Study Group

818 **Hepatitis C virus-related thrombocytopenia: clinical and laboratory characteristics compared with chronic immune thrombocytopenic purpura**
S. K. Rajan, B. M. Espina and H. A. Liebman

Short report 825 **Genetic analysis in FXI deficiency: six novel mutations and the use of a polymerase chain reaction-based test to define a whole gene deletion**
M. Hill, F. McLeod, H. Franks, B. Gordon and G. Dolan

Haemopoiesis and Leucocytes

830 **Cryoglobulin-induced cytokine production via FcγRIIa: inverse effects of complement blockade on the production of TNF-α and IL-10. Implications for the growth of malignant B-cell clones**
L. Mathsson, A. Tejde, K. Carlson, M. Höglund, B. Nilsson, K. Nilsson-Ekdahl and J. Rönnelid

Red Cells and Iron

839 **Red cell pyruvate kinase deficiency: 17 new mutations of the *PK-LR* gene**
E. Fermo, P. Bianchi, L. R. Chiarelli, F. Cotton, C. Vercellati, K. Writzl, K. Baker, I. Hann, R. Rodwell, G. Valentini and A. Zanella

847 **Recessive congenital methaemoglobinaemia: functional characterization of the novel D239G mutation in the NADH-binding lobe of cytochrome b_5 reductase**
M. J. Percy, L. J. Crowley, C. A. Davis, M. F. McMullin, G. Savage, J. Hughes, C. McMahon, R. J. M. Quinn, O. Smith, M. J. Barber and T. R. J. Lappin

Announcements

854 **First International Conference on Hypertension, Lipids, Diabetes and Stroke Prevention**

855 **Ninth International Workshop on Langerhans Cells – Funchal, Madeira, Portugal**

856 **Author Index**

859 **Keyword Index**